Effect of troglitazone on body fat distribution in type 2 diabetic patients.

摘要: OBJECTIVE: Troglitazone was recently reported to specifically promote the differentiation of pre-adipocytes into adipocytes in vitro subcutaneous fat only, indicating a relation insulin-resistance-improving action troglitazone. To expand on this finding, we investigated at clinical level how long-term administration troglitazone influences body distribution type 2 diabetic patients. RESEARCH DESIGN AND METHODS: (400 mg/day) administered for 6 months 30 patients whose glycemic control poor. A total 18 received diet therapy alone (in single-treatment group, BMI 26.0 +/- 4.6, HbA1c 8.2 1.7%), and 12 concomitantly glibenclamide (1.25-7.5 concomitant sulfonylurea 25.4 4.7, 9.2 1.2%). BMI, HbA1c, serum lipid level, distribution, which were determined by computed tomography (CT) scan umbilical measured compared before after treatment. RESULTS: During 6-month treatment, levels decreased increased both groups. As visceral area (VFA) (from 118.3 54.3 101.1 50.8 cm2; P